Study of efficacy and safety of iptacopan in patients with C3 glomerulopathy

Phase 3

• Conditions: Health Condition 1: N036- Chronic nephritic syndrome with dense deposit diseaseHealth Condition 2: N033- Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis

• Registration Number: CTRI/2021/10/037351
• Lead Sponsor: ovartis Healthcare Pvt Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 January 2023

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Diagnosis of C3G as confirmed by renal biopsy within 12 months prior to enrollment (a biopsy report, review and confirmation by the Investigator is required). If such a biopsy is not available, confirmation may be obtained using tissue from the Day -45 biopsy for local assessment.

Prior to randomization, all participants must have been on a maximally recommended or tolerated dose of an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) for at least 90 days. The doses of other antiproteinuric medications including mycophenolic acids, corticosteroids and mineralocorticoid receptor antagonists should be stable for at least 90 days prior to randomization.

Reduced serum C3 (defined as less than 0.85 x lower limit of the central laboratory normal range) at Screening.

UPCR >= 1.0 g/g sampled from the first morning void urine sample at Day -75 and Day -15.

Estimated GFR (using the CKD-EPI formula) or measured GFR >= 30 ml/min/1.73m2 at screening and Day -15.

Vaccination against Neisseria meningitidis infection prior to the start of study treatment. If the patient has not been previously vaccinated, or if a booster is required, the vaccine should be given according to local regulations at least 2 weeks prior to the first administration of study treatment. If study treatment has to start earlier than 2 weeks post vaccination, prophylactic antibiotic treatment should be initiated.

If not previously vaccinated, or if a booster is required, vaccination against Streptococcus pneumoniae and Haemophilus influenzae infections should be given, if available and according to local regulations, at least 2 weeks prior to the first study treatment administration. If study treatment has to start earlier than 2 weeks post vaccination, prophylactic antibiotic treatment should be initiated.

Exclusion Criteria

Participants who have received any cell or organ transplantation, including kidney transplantation.

Rapidly progressive crescentic glomerulonephritis defined as a 50% decline in the eGFR within 3 months) with renal biopsy findings of glomerular crescent formation seen in at least 50% of glomeruli.

Renal biopsy showing interstitial fibrosis/tubular atrophy (IF/TA) of more than 50%.

Monoclonal gammopathy of undetermined significance (MGUS) confirmed by the measurement of serum free light chains or other investigation as per local standard of care.

Participants with an active systemic bacterial, viral or fungal infection within 14 days prior to study treatment administration or the presence of fever >= 38°C (100.4°F) within 7 days prior to study treatment administration.

A history of recurrent invasive infections caused by encapsulated organisms, e.g., meningococcus or pneumococcus.

The use of inhibitors of complement factors (e.g., Factor B, Factor D, C3 inhibitors, anti Complement 5 (C5) antibodies, C5a receptor antagonists) within 6 months prior to the Screening visit.

The use of immunosuppressants (except mycophenolic acids), cyclophosphamide or systemic corticosteroids at a dose >7.5 mg/day (or equivalent for a similar medication) within 90 days of study drug administration.

Study & Design

• Study Type: Interventional
• Study Design: Not specified